Business Context and Reporting Period
Company: Ingevity Corp
Filing Type: Form 8-K (Current Report)
Date of Report: February 13, 2019
Event: Completion of the acquisition of the Capa™ caprolactone division from Perstorp Holding AB.
Key Financial Metrics
This filing reports transaction-specific financial data rather than ongoing operational metrics (revenue, profit, cash flow, or margins) for the reporting period.
| Metric | Value (EUR) | Value (USD) |
|---|---|---|
| Purchase Price | €578.9 million | $652.5 million |
| Net Debt Assumed | €100.4 million | $113.1 million |
| Funding Source | Borrowings under existing credit facilities and cash on hand |
Liquidity and Debt: The assumed net debt was settled at closing with an affiliate of the counterparty. The filing does not provide updated total debt or liquidity positions for Ingevity Corp post-transaction.
Material Changes
- Asset Acquisition: Ingevity completed the purchase of the Capa™ caprolactone division, expanding its specialty chemicals portfolio.
- Balance Sheet Impact: The transaction involved assuming €100.4 million in net debt, which was immediately settled with the seller's affiliate.
- Capital Structure: The acquisition was funded via a mix of existing credit facility borrowings and internal cash reserves.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) regarding the completion but does not include specific forward-looking guidance or management commentary within the text of this 8-K.
Contingencies and Unusual Items:
- Financial Statements: The Company intends to file required financial statements of the acquired business and pro forma financial information by amendment within 71 calendar days of this filing date.
- Agreement Details: The summary is qualified by the full text of the Stock Purchase Agreement filed as Exhibit 2.1.
Investor Verification Checklist
- Verify the final purchase price and debt assumption figures in the definitive Stock Purchase Agreement (Exhibit 2.1).
- Monitor the upcoming amendment (due within 71 days) for the acquired business's financial statements and pro forma financial information.
- Review the press release (Exhibit 99.1) for strategic rationale and immediate operational impacts not detailed in the 8-K.
- Assess the impact of the new borrowings on Ingevity's existing credit facility covenants and leverage ratios.